The Global cancer biomarkers market boasts a total value of $12.4 billion in 2022 and is projected to register a growth rate of 17.7% to reach a value of $28.2 billion by 2030. The report attributes this growth to the increasing prevalence of cancer, the development of new biomarker detection technologies, and the availability of large amounts of genomic data.

Browse 215 market data Tables and 96 Figures spread through 312 Pages and in-depth TOC on "Cancer Biomakers Market Size, Share & Trends Estimation Report By Outlook, By Region, And Segment Forecasts, 2022 - 2030" View detailed Table of Content here-https://www.contrivedatuminsights.com/product-report/cancer-biomakers-market-248691/

The global cancer biomarkers market refers to the market for diagnostic and prognostic tools that detect cancer by measuring biomolecules such as proteins, genes, and other markers in the body. These biomarkers can indicate the presence of cancer, its stage, and its aggressiveness.

Market Dynamics

The market for cancer biomarkers is driven by the increasing incidence of cancer worldwide, as well as the growing demand for personalized medicine and targeted therapies. The market is also fueled by the development of new biomarker detection technologies and the availability of large amounts of genomic data.

Increasing incidence of cancer: The prevalence of cancer is increasing worldwide due to factors such as an aging population, lifestyle changes, and exposure to environmental risk factors. This has led to a growing demand for early detection and personalized treatment options, driving the market for cancer biomarkers.

Advancements in biomarker detection technologies: Advances in technologies such as next-generation sequencing, immunoassays, and polymerase chain reaction (PCR) have enabled the identification and measurement of a wide range of cancer biomarkers. This has led to the development of more accurate and reliable diagnostic and prognostic tools, driving market growth.

High cost of biomarker tests: The cost of biomarker tests can be high, making them inaccessible to patients in low-income countries or those without access to comprehensive health insurance. This could limit the adoption of these tests, especially in resource-limited settings.

Increasing focus on personalized medicine: There is a growing trend towards personalized medicine, which involves the use of biomarkers to identify patients who are most likely to benefit from specific therapies. This presents an opportunity for companies operating in the cancer biomarkers market to develop new biomarker tests that can help personalize cancer treatment.

Prostate cancer is the most common cancer in men. Biomarkers such as prostate-specific antigen (PSA) are used for the diagnosis and management of prostate cancer. Colorectal cancer is the third most common cancer worldwide. Biomarkers such as carcinoembryonic antigen (CEA) and KRAS mutations are used for the diagnosis and management of colorectal cancer.

Melanoma is a type of skin cancer. Biomarkers such as BRAF mutations and programmed cell death protein 1 (PD-1) are used for the diagnosis and management of melanoma.

Leukemia and lymphoma are types of blood cancers. Biomarkers such as B-cell lymphoma 2 (BCL-2) and B-cell receptor (BCR) signaling pathway mutations are used for the diagnosis and management of these cancers.

Regional Analysis

Europe is the second-largest market for cancer biomarkers owing to the increasing prevalence of cancer and growing awareness about early diagnosis and treatment. The UK, Germany, France, and Italy are the major contributors to the market growth in the region. The European Union has launched several initiatives to promote cancer research and improve patient outcomes.

Asia-Pacific is expected to be the fastest-growing region in the global cancer biomarkers market due to the increasing incidence of cancer and the growing demand for advanced diagnostic tools. China, India, Japan, and South Korea are the major markets in the region. The market growth is also driven by the increasing investments in healthcare infrastructure and rising healthcare expenditure.

Competitive Analysis

The major players in the global cancer biomarkers market include Roche Diagnostics, Abbott Laboratories, Thermo Fisher Scientific, Illumina, and Qiagen, among others. These companies are investing heavily in research and development activities to develop innovative biomarker detection technologies and expand their product portfolios.

Thermo Fisher Scientific is a leading player in the global cancer biomarkers market, offering a range of products for cancer diagnosis and treatment. The company's portfolio includes several biomarker-based products, such as Oncomine Dx Target Test, which is used for the detection of solid tumor mutations.

Abbott Laboratories is a major player in the global cancer biomarkers market, offering a range of products for cancer diagnosis and treatment. The company's portfolio includes several biomarker-based products, such as Vysis ALK Break Apart FISH Probe Kit, which is used for the detection of ALK gene rearrangement in non-small cell lung cancer.

Qiagen is a leading player in the global cancer biomarkers market, offering a range of products for cancer diagnosis and treatment. The company's portfolio includes several biomarker-based products, such as therascreen KRAS RGQ PCR Kit, which is used for the detection of KRAS mutations in colorectal cancer.

In February 2021, Illumina acquired Grail, a company that is developing a blood test for early cancer detection, for $8 billion. This acquisition is expected to strengthen Illumina's position in the cancer diagnostics market.

In September 2020, Qiagen completed the acquisition of the remaining shares of NeuMoDx Molecular, a company that develops and produces automated molecular diagnostic tests. This acquisition is expected to expand Qiagen's portfolio of molecular diagnostics products.

In August 2020, Thermo Fisher Scientific acquired Qiagen for $11.5 billion. This acquisition is expected to strengthen Thermo Fisher Scientific's position in the life sciences market and expand its portfolio of molecular diagnostics products.

In July 2020, Roche announced that it had received FDA approval for its Elecsys® EGFR Mutation Test v2, a blood-based test for the detection of EGFR mutations in non-small cell lung cancer patients.

In March 2020, Illumina and Roche announced a 15-year partnership to develop and distribute in-vitro diagnostic tests based on Illumina's sequencing technology. This partnership is expected to accelerate the development of next-generation sequencing-based diagnostic tests for cancer.

In January 2020, Abbott Laboratories acquired Cephea Valve Technologies, a company that is developing a minimally invasive heart valve replacement system. This acquisition is expected to expand Abbott Laboratories' portfolio of cardiovascular devices and therapies.

These developments, mergers, and investments indicate the growing interest in the cancer biomarkers market and the potential for further growth and innovation in the field.

Segmentation Analysis of The Global Cancer Biomakers Market 2016-2030

The report forecasts revenue growth at global, regional, and country matrics and analyzes the latest industry trends in each of the sub-segments ranging from 2016-2030. For this, CDI has segmented the global Cancer Biomakers market report based on capacity, vehicle, application, and propulsion type along with regional analysis. 

By Profiling Technology

• Omic Technologies
• Imaging Technologies
• Immunoassays
• Cytogenetics-based Tests

By Biomolecule

• Genetic Biomarkers
• Protein Biomarkers
• Glyco-biomarkers

By Cancer Type

• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Stomach Cancer
• Others

By Application

• Diagnostics
• Drug Discovery and Development
• Prognostics
• Risk Assessment
• Others

Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America
• US
• Canada
• Mexico
• Rest of North America
• Europe
  • Germany
  • France
  • Italy
  • Spain
  • UK
  • Nordic Countries
    • Denmark
    • Finland
    • Iceland
    • Sweden
    • Norway
  • Benelux Union
    • Belgium
    • The Netherlands
    • Luxembourg
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Southeast Asia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Rest of Southeast Asia
• Rest of Asia-Pacific
• The Middle East & Africa
• Saudi Arabia
• UAE
• Egypt
• South Africa
• Rest of the Middle East & Africa
• Latin America
• Brazil
• Argentina
• Rest of Latin America